Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 4;2(3):otaa041.
doi: 10.1093/crocol/otaa041. eCollection 2020 Jul.

Risk of Uveitis in Patients With Inflammatory Bowel Disease on Immunosuppressive Drug Therapy

Julie Barberio  1 , Seoyoung C Kim  1   2 , Miin Roh  3 , James D Lewis  4 , Rishi J Desai  1
Affiliations
Review

Risk of Uveitis in Patients With Inflammatory Bowel Disease on Immunosuppressive Drug Therapy

Julie Barberio et al. Crohns Colitis 360. .

Abstract

Background: Inflammatory bowel disease (IBD) patients may develop anterior uveitis.

Methods: An observational cohort of IBD patients followed new users of (1) tumor necrosis factor inhibitor versus nonbiologic agents or (2) adalimumab versus infliximab until occurrence of anterior uveitis or treatment change/discontinuation. Cox-proportional hazards models estimated hazard ratios in propensity score-matched cohorts of Crohn disease or ulcerative colitis patients.

Results: No statistically significant differences in the risk of uveitis were observed between initiators of nonbiologics and tumor necrosis factor inhibitor. Effect estimates for adalimumab versus infliximab were highly imprecise due to limited outcomes.

Conclusions: Uveitis risk was not different between IBD patients treated with immunosuppressives.

Keywords: adalimumab; inflammatory bowel disease; infliximab; uveitis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow chart for patient selection, shown separately for (A) nonbiologic immunosuppressive drug-exposed versus TNFi-exposed patients and (B) adalimumab-exposed versus infliximab-exposed patients.
Figure 2.
Figure 2.
Hazard ratios and 95% confidence intervals for the outcome of anterior noninfectious uveitis in the propensity score-matched cohorts: (1) nonbiologic immunosuppressive drug-exposed versus TNFi-exposed patients and (2) adalimumab-exposed versus infliximab-exposed patients.
See this image and copyright information in PMC

References

    1. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504–1517. - PubMed
    1. Kappelman MD, Rifas–Shiman SL, Kleinman K, et al. . The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424–9. - PubMed
    1. Burisch J, Jess T, Martinato M, et al. ; ECCO-EpiCom . The burden of inflammatory bowel disease in Europe. J Crohns Colitis 2013;7:322–337. - PubMed
    1. Longobardi T, Jacobs P, Wu L, Bernstein CN. Work losses related to inflammatory bowel disease in Canada: results from a National Population Health Survey. Am J Gastroenterol. 2003;98:844–849. - PubMed
    1. Karmiris K, Avgerinos A, Tavernaraki A, et al. . Prevalence and characteristics of extra-intestinal manifestations in a large cohort of Greek patients with inflammatory bowel disease. J Crohns Colitis 2016;10:429–36. - PMC - PubMed

LinkOut - more resources